Iron sucrose

Modify Date: 2024-01-02 18:54:45

Iron sucrose Structure
Iron sucrose structure
 Common Name Iron sucrose
CAS Number 8047-67-4 Molecular Weight 736.059
Density N/A Boiling Point 766.4ºC at 760 mmHg
Molecular Formula C18H24Fe2O24 Melting Point MORE THAN 51ºC
MSDS N/A Flash Point 431.2ºC

 Use of Iron sucrose


Iron sucrose (Iron saccharate) is a intravenous iron preparation and a pro-oxidant agent. Iron sucrose has the potential for iron deficiency anemia treatment[1][2][3][4].

 Names

Name Iron saccharate
Synonym More Synonyms

 Iron sucrose Biological Activity

Description Iron sucrose (Iron saccharate) is a intravenous iron preparation and a pro-oxidant agent. Iron sucrose has the potential for iron deficiency anemia treatment[1][2][3][4].
Related Catalog
In Vitro Intravenous Iron sucrose results in a statistically significant increase in hemoglobin, mean corpuscular volume, serum iron, ferritin, and % iron saturation, with a corresponding decrease in total iron binding capacity[1]. In vitro survival assays show that 10 mM ascorbate exposure (2h) clonogenically inactivated 40-80% of exponentially growing colon cancer cell lines (HCT116 and HT29). When colon cancer cells are treated in the presence or absence of 250 µM Iron sucrose, then rinsed, and treated with 10 mM ascorbate, the cells demonstrate increased levels of labile iron that results in significantly increased clonogenic cell killing, compared to pharmacological ascorbate alone[2]. The expression levels of intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and adhesion of U937 cells increased in Iron sucrose-treated human aortic endothelial cells through upregulated NADPH oxidase (NOx) and NF-κB signaling. Iron sucrose significantly induces a time-dependent increase in intracellular ROS production in HAECs between 1 and 3 hours at a concentration of 160 μg/mL, but the effect diminished at 4 hours[3].
In Vivo Iron sucrose significantly increases tissue superoxide production, expression of tissue cell adhesion molecules, and endothelial adhesiveness in mice with subtotal nephrectomy. Iron sucrose exacerbates atherosclerosis in the aorta of ApoE-/- mice with uninephrectomy[3].
References

[1]. Kristiyana Kaneva, et al. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262.

[2]. Kristin E Brandt, et al. Augmentation of Intracellular Iron Using Iron Sucrose Enhances the Toxicity of Pharmacological Ascorbate in Colon Cancer Cells. Redox Biol. 2018 Apr;14:82-87.

[3]. Ko-Lin Kuo, et al. Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD. J Am Soc Nephrol. 2014 Nov;25(11):2596-606.

[4]. Richard A Zager, et al. Combined Iron Sucrose and Protoporphyrin Treatment Protects Against Ischemic and Toxin-Mediated Acute Renal Failure. Kidney Int. 2016 Jul;90(1):67-76.

 Chemical & Physical Properties

Boiling Point 766.4ºC at 760 mmHg
Melting Point MORE THAN 51ºC
Molecular Formula C18H24Fe2O24
Molecular Weight 736.059
Flash Point 431.2ºC
Exact Mass 735.935608
PSA 483.54000

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NO7700000
CHEMICAL NAME :
Iron oxide, saccharated
CAS REGISTRY NUMBER :
8047-67-4
LAST UPDATED :
199512

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
180 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,193,1982
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
150 mg(Fe)/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 10,375,1955 ** TUMORIGENIC DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1560 mg/kg/13W-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - other reproductive system tumors
REFERENCE :
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 60,708,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
148 gm/kg/74W-I
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Tumorigenic - tumors at site of application
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,947,1959
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
104 gm/kg/13W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application
REFERENCE :
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8. Volume(issue)/page/year: 24,109,1960
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
150 gm/kg/I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease Tumorigenic - tumors at site of application
REFERENCE :
BECCAN Annual Report--Cancer Research Campaign. (Cancer Research Campaign, 2 Carlton House Terrace, London SW1Y 5AR, UK) V.1- 1924- Volume(issue)/page/year: 40,30,1962 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 2,161,1973 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 2,161,1973 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW PEXTAR Progress in Experimental Tumor Research. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.1- 1960- Volume(issue)/page/year: 12,102,1969

 Safety Information

HS Code 3004909090

 Customs

HS Code 3004909090

 Synonyms

Venofer
ferrivenin
Sucrofer
EINECS 232-464-7
MFCD00166305
Fesin
Hippiron
Iron(3+) D-glucarate (2:3)
ironsugar
iviron
proferrin
feojectin
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Iron sucrose suppliers

Iron sucrose price

Related Compounds: More...
Iron, glycerol sucrose complexes
90412-15-0
iron(iii) citrate hydrate, 98
334024-15-6
IRON SILICIDE
58320-11-9
iron,samarium (7:2)
68777-35-5
Iron chloride oxide
56509-17-2
Iron(2+),tris(2,2'-bipyridine-N,N')-, diiodide, (OC-6-11)- (9CI)
15388-60-0
Iron oxide brown
52357-70-7
Iron(II) ethylenediammonium sulfate tetrahydrate
34962-29-3
iron(3+) sodium disulphate
13939-33-8
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
tert-Butyl-DL-alanine
1375289-11-4
4-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-ethylbenzenesulfonamide
849349-65-1
N-[3-(Aminooxy)propyl]-N-butyl-1-butanamine
127437-46-1
Chemsrc provides Iron sucrose(CAS#:8047-67-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Iron sucrose are included as well.>> amp version: Iron sucrose

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved